Skip to main content

Table 3 Relations between median levels of FGF-23 and measurements of cardiac structure, function and perfusion

From: Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics

 

Fibroblast growth factor-23

P-value

Below the median

Above the median

LVEF (%)

63 ± 8

63 ± 7

0.92

EDV (ml)

153 ± 35

154 ± 37

0.91

EDV index (ml/m2)

72 ± 13

70 ± 15

0.29

ESV (ml)

58 ± 22

59 ± 24

0.75

ESV index (ml/m2)

27 ± 9

27 ± 10

0.78

SV (ml)

95 ± 21

95 ± 20

0.89

LV mass (g)

138 ± 36

143 ± 40

0.04

LV mass index (g/m2)

62 ± 13

66 ± 16

0.03

LA volume (ml)

91 ± 25

97 ± 27

0.07

LA volume index (ml/m2)

41 ± 11

44 ± 11

0.10

Rest MBF (ml/min/g)

0.81 ± 0.19

0.83 ± 0.18

0.69

Stress MBF (ml/min/g)

2.7 ± 0.9

2.3 ± 0.9

0.001

MPR

3.3 ± 1.1

2.7 ± 0.8

 < 0.001

Average E/e*

7.6 ± 2.7

8.5 ± 3.2

0.04

Extracellular volume (%)

27.8 ± 3.5

28.6 ± 3.2

0.51

  1. Data presented as mean ± SD. LVEF left ventricular ejection fraction, EDV end-diastolic volume, ESV end-systolic volume, SV stroke volume, LA left atrial, MBF myocardial blood flow, MPR myocardial perfusion reserve. Significant differences indicated in bold.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840